This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Finland
Abacus Diagnostica Oy is a Finnish molecular diagnostics company specialized in rapid DNA testing utilizing its proprietary GenomEra?-technology. Company's mission is to provide innovative and simple-to-use solutions to enable routine use of DNA based testing without compromising the quality of results and move the molecular diagnostic to the next level of easiness.
DelSiTech Ltd specialises in a silica-based technology for controlled release of small molecular drugs and biopharmaceuticals: proteins, polysaccharides (heparin) and viruses.
Faron Pharmaceuticals, Ltd. is a Finnish drug discovery and development company based in Turku. The Company has three major drug development projects focusing on acute trauma, inflammatory diseases, and cancer/metastasis growth. The three Faron's drug target molecules, two enzymes (AOC3/SSAO and CD73/5?-nucleotidase) and one adhesion receptor (CLEVER-1), are all expressed, either to endothelial cell surfaces of blood or lymphatic vessels, or to both.
FIT Biotech is an innovative medical biotechnology company engaged in the development and commercialisation of its proprietary Gene Transport Unit (GTU) technology and GTU product applications in DNA vaccination as well as in immuno- and gene therapies.They are engaged especially in researching and developing an HIV vaccine.
Forendo Pharma Oy operates as a drug discovery and development company. The company focuses on tissue specific regulation of sex hormone effects. The company?s product candidates are fispemifene, a program with positive Phase II data aimed at treatment of low testosterone levels, and 17B-HSD1 enzyme inhibitors, aimed at treatment of endometriosis.
Hermo Pharma Ltd. aims at developing novel disease-modifying treatments for Parkinson?s disease and other neurodegenerative diseases. The company?s R&D programs are based on scientifically innovative concepts. These concepts are being developed by the company through preclinical and clinical Phase II proof-of-principal trials and after that Hermo Pharma will seek partnerships to support Phase III trials and market its products worldwide. Currently Hermo Pharma?s product development focus is on novel disease-modifying treatments for amblyopia in adults and Parkinson?s disease.
Medeia is a drug discovery company dedicated to generate and carry out early non-clinical development of novel small molecule therapeutics for human degenerative diseases focusing especially on CNS indications such as Alzheimer?s disease, Parkinson?s disease and amyotrophic lateral sclerosis as well as hormonal oncology.
Medeia is committed to seeking partnerships with global pharmaceutical and biotech companies to advance their products further to clinical trials and eventually to the market. They collaborate with Orion Corp. in one of their most advanced program.
Medeia is committed to seeking partnerships with global pharmaceutical and biotech companies to advance their products further to clinical trials and eventually to the market. They collaborate with Orion Corp. in one of their most advanced program.
Mobidiag is a Finnish molecular diagnostics company specializing in rapid diagnostics of infectious diseases.
Oncos Therapeutics develops and manufactures therapeutic cancer vaccines based on next generation oncolytic adenoviruses. They have designed their products in development based on data from clinical treatment of 290 cancer patients. Their lead product is now entering phase II clinical trials for first line treatment of solid tissue sarcoma, a poorly served orphan indication.
Paras Finland ( Europe) is a fast growing biopharmaceutical technology development company which has successfully developed the propriety Diabrid Platform Technology for the high level expression of biosimilars and long therapeutic peptides in specially designed genetically stable clones.
Paras Biopharmaceuticals Finland Oy is specialized in design, development and optimization of manufacturing technologies for therapeutic peptides and soon to be off patent biologics. The Company is building a robust portfolio of propriety technologies and have developed extensive intellectual property.
Paras has developed multiple novel technologies,
1. Diabrid Technology
2. Noble CleavR Technoloiges
3. BiomultifoldR Technology
4. Cytoplasmic Protein Folding Technologies
Paras Biopharmaceuticals Finland Oy is specialized in design, development and optimization of manufacturing technologies for therapeutic peptides and soon to be off patent biologics. The Company is building a robust portfolio of propriety technologies and have developed extensive intellectual property.
Paras has developed multiple novel technologies,
1. Diabrid Technology
2. Noble CleavR Technoloiges
3. BiomultifoldR Technology
4. Cytoplasmic Protein Folding Technologies